AbbVie Inc.: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-07-05
Other years: 2026 vs 2025 · 2025 vs 2024
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

0
New Risks
0
Removed
4
Modified
27
Unchanged
🟡 Modified AbbVie depends on information technology and a failure of, or significant disruption to, those systems could have a material adverse effect on AbbVie's business. 🔒
🟡 Modified The international nature of AbbVie's business subjects it to additional business risks that may cause its revenue and profitability to decline. 🔒
🟡 Modified Public health outbreaks, epidemics or pandemics, such as the coronavirus (COVID-19), have had, and could in the future have, an adverse impact on AbbVie’s operations and financial condition. 🔒
🟡 Modified AbbVie is subject to cost-containment efforts and pricing pressures that could cause a reduction in revenues and operating earnings, and changes in the terms of rebate and chargeback programs, which are common in the pharmaceuticals industry, could have a material adverse effect on AbbVie's operations. 🔒
4 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →